Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence | MicrobiomeTrials
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2018-08-20Est. Completion: 2029-01-01
Enrollment target: 240 participants
Locations
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Siteman Cancer Center at Washington University, St Louis, Missouri, United States
M D Anderson Cancer Center, Houston, Texas, United States
Institut de Cancérologie de l'Ouest (ICO), Angers, France
CHU Angers, Hôpital Larrey, Angers, France
CHU Besançon, Hôpital Jean Minjoz, Besançon, France
CHU Brest, Hôpital La Cavale Blanche, Brest, France
Centre Georges François Leclerc, Dijon, France
Lyon HCL, Lyon, France
HCL Hôpital Louis Pradel, Lyon, France
Marseille Hôpital Nord, Marseille, France
Marseille Hôpital de la Conception, Marseille, France
CHU Nantes, Hôpital René et Guillaume Laënnec, Nantes, France
CHU Nantes, Hôpital René et Guillaume Laënnec, Nantes, France
Hôpital Cochin, AP-HP, Paris, France
Hôpital Cochin, AP-HP, Paris, France
Hôpital Cochin, Paris, France
Hôpital COCHIN, Paris, France
Other microbiome trials you might be interested in